Debiopharm International SA
- Country
- 🇨🇭Switzerland
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://debiopharm.com
A Single Dose Study of Debio 1450 in Healthy Subjects
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 48
- Registration Number
- NCT02162199
- Locations
- 🇺🇸
Early Phase Clinical Unit, Baltimore, Maryland, United States
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 52
- Registration Number
- NCT02094443
- Locations
- 🇫🇷
Novartis Investigative Site, Paris, France
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
- Conditions
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 144
- Registration Number
- NCT02022098
- Locations
- 🇫🇷
C.H.U. Sud Amiens, Amiens, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand Cedex 01, France
🇫🇷Centre Hospitalier de Bretagne Sud - HÔPITAL DU SCORFF, Lorient, Bp 2233, France
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 16
- Registration Number
- NCT01975337
- Locations
- 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
- Conditions
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 147
- Registration Number
- NCT01970904
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 77
- Registration Number
- NCT01948297
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Hospital, New York, New York, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 31
- Registration Number
- NCT01930292
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷Institut Curie, Paris, France
🇫🇷Centre Léon Bérard, Lyon, France
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 32
- Registration Number
- NCT01860326
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
- Conditions
- Interventions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 82
- Registration Number
- NCT01714037
- Locations
- 🇫🇷
Centre GF Leclerc, Dijon, France
🇫🇷Institut de Cancérologie de l'Ouest- Institut René Gauduchau, Nantes, France
🇫🇷Centre Léon Bérard, Lyon, France
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 120
- Registration Number
- NCT01656161
- Locations
- 🇿🇦
East Rand Urology Research Unit, Clinix Private Clinic, Johannesburg, Gautang, South Africa
🇿🇦Paarl Medical Centre, Paarl, Cape Town, Western Cape, South Africa
🇿🇦Department of Urology, Tygerberg Hospital, Tygerberg, Cape Town, South Africa